Bicara Therapeutics Inc.
BCAX
$11.32
-$0.52-4.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.19M | 22.88M | 18.77M | 15.14M | 12.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 121.07M | 108.80M | 82.39M | 69.44M | 58.34M |
| Operating Income | -121.07M | -108.80M | -82.39M | -69.44M | -58.34M |
| Income Before Tax | -102.36M | -92.08M | -67.81M | -59.47M | -64.84M |
| Income Tax Expenses | 310.00K | 258.00K | 187.00K | 6.00K | 6.00K |
| Earnings from Continuing Operations | -102.67 | -92.33 | -68.00 | -59.48 | -64.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.67M | -92.33M | -68.00M | -59.48M | -64.84M |
| EBIT | -121.07M | -108.80M | -82.39M | -69.44M | -58.34M |
| EBITDA | -121.00M | -108.74M | -82.33M | -69.38M | -58.30M |
| EPS Basic | -3.17 | -21.68 | -39.94 | -59.31 | -95.93 |
| Normalized Basic EPS | -1.98 | -13.55 | -24.96 | -37.06 | -59.95 |
| EPS Diluted | -3.17 | -21.68 | -39.94 | -59.31 | -95.93 |
| Normalized Diluted EPS | -1.98 | -13.55 | -24.96 | -37.06 | -59.95 |
| Average Basic Shares Outstanding | 174.32M | 120.68M | 66.88M | 13.09M | 2.78M |
| Average Diluted Shares Outstanding | 174.32M | 120.68M | 66.88M | 13.09M | 2.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |